- €189.42m
- €98.76m
- €6.86m
Brief: Transgene Launches Capital Increase Via Private Placement Of 32 Million Euros
Brief: Transgene Strengthens Global IP Protection For Its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
Brief: Bioinvent And Transgene Receive Approval From FDA For Bt-001
Brief: Transgene And Bioinvent Receive IND Approval From FDA For BT-001
Brief: Transgene Q1 Operating Revenue Down At 2.4 Million Euros
Brief: Transgene Presents Initial Phase I Data Of TG6002
Brief: Transgene Expands Phase II Clinical Trial Of Therapeutic Vaccine TG4001
Brief: Transgene Announces Financial Visibility Until 2022
Brief: Transgene And BioInvent Enrol First Patient In Phase I/IIa Of Oncolytic Virus BT-001 Trial
Brief: Transgene: First Head & Neck Cancer Patient Treated In France In Phase I Trial With TG4050
Brief: Transgene, Bioinvent Get ANSM Approval For Phase I/IIa Trial
Brief: Transgene And Bioinvent Receive CTA Approval For Phase 1/2A Trial Of Oncolytic Virus BT-001 In Solid Tumors
Brief: Transgene Appoints Hedi Ben Brahim As Chairman And CEO
Brief: Transgene Presents The Detailed Results From Phase 1b/2 Trial Combining TG4001 with avelumab (BAVENCIO®)
Brief: Transgene Reports End-September Cash And Cash Equivalents Of EUR 45.3 Million
Brief: Transgene Announces Results From Clinical Study Of TG4001 In Combination With Avelumab
Brief: Transgene, NEC And BostonGene Announce Strategic Collaboration For Two Ongoing Clinical Trials
Brief: Transgene H1 Net Comprehensive Loss At 2.2 Million Euros
Brief: Transgene: Positive Initial Data From A Phase 1 Trial With Oncolytic Virus TG6002